April 25, 2018

The FDA Approves JYNARQUE™ as the First Treatment in the United States for Adult Patients with ADPKD

We’re excited to announce that on Tuesday, April 24, 2018, the U.S. Food and Drug Administration (FDA) granted approval of JYNARQUE™ (pronounced jin-AR-kew and also known as tolvaptan) to be the first treatment in the United States for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease (PKD).

JYNARQUE™ slows the growth of cysts and the progression of the disease and has been shown to preserve kidney function. The treatment for ADPKD is an oral pill taken twice a day. It is a long-term use drug – extending the time before a patient needs dialysis or a transplant, though not curing the disease. JYNARQUE™ (brand name JINARC™ in Canada) was developed by Otsuka Pharmaceuticals.

Special JYNARQUE™ Webinar

Learn more about JYNARQUE™ by registering for the PKD Foundation (USA) webinar with Ronald Perrone, M.D., on Monday, April 30.

Register for the webinar here.